A Phase II Study of the CXCR2 Antagonist Navarixin in Combination with Pembrolizumab for Patients with Advanced Castration-Resistant Prostate Cancer, Microsatellite-Stable Colorectal Cancer, or Non-Small-Cell Lung Cancer. The gene discussed is CXCR2; the disease is colorectal cancer.